PURA Potential Rises With Growing Interest From Brands Including Coca-Cola and CVS In CBD Infused Products
June 25 2019 - 9:05AM
InvestorsHub NewsWire
PURA Potential Rises With Growing
Interest From Brands Including Coca-Cola and CVS In CBD Infused
Products
Dallas, TX -- June 25, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) the producer of EVERx CBD Sports Water, the
leading CBD infused beverage in the sports nutrition market today
highlighted the Washington Post article published yesterday on
the growing market demand for CBD infused foods and
beverages.
“Brands as
diverse as Ben &
Jerry’s and Coca-Cola are chomping at the bit to launch CBD-infused
products, and stores like
Walgreens, Kroger and CVS have vowed to sell them. More than 1,000
CBD-infused products are now available
online.”
Management
indicates the company has had conversation with more than one major
brand name.
PURA Speculative
Buy Recommendation and $0.25 PPS Target w/Potential to
$0.35
Goldman Small Cap Research recently
released a new research report recommending PURA as a
Speculative
BUY with a $0.25 PPS Target. Goldman Small Cap Research further
reports that the shares of PURA “have the potential to reach the
$0.35 mark.” The report highlights PURA’s growing EVERx CBD
Sports Water sales and the coming introduction of new beverages as
well as the potential for the company to exceed its 2019 sales
targets through the pending doubling of its production capacity and
through planned acquisitions.
PURA achieved over $1 million in sales in
2018 and is well on its way toward a targeted $4 million in sales
in 2019. PURA is the sole license of a U.S. Patented Cannabis
Extraction Process owned by Kali-Extracts, Inc. (aka Kali, Inc.)
(USOTC:
KALY) (“KALY”).
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024